Scynexis Inc - Asset Resilience Ratio
Scynexis Inc (SCYX) has an Asset Resilience Ratio of 31.80% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SCYX working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Scynexis Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see SCYX total asset value.
Liquid Assets Composition Over Time
This chart breaks down Scynexis Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore SCYX strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $18.77 Million | 31.8% |
| Total Liquid Assets | $18.77 Million | 31.80% |
Asset Resilience Insights
- Very High Liquidity: Scynexis Inc maintains exceptional liquid asset reserves at 31.80% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Scynexis Inc Industry Peers by Asset Resilience Ratio
Compare Scynexis Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 1.01% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
Annual Asset Resilience Ratio for Scynexis Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Scynexis Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 47.71% | $43.25 Million | $90.64 Million | +16.32pp |
| 2023-12-31 | 31.39% | $40.31 Million | $128.41 Million | -0.14pp |
| 2022-12-31 | 31.53% | $27.69 Million | $87.81 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $119.84 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $102.54 Million | -- |
| 2019-12-31 | 11.36% | $6.49 Million | $57.15 Million | -50.17pp |
| 2018-12-31 | 61.53% | $32.72 Million | $53.17 Million | -9.18pp |
| 2017-12-31 | 70.72% | $32.42 Million | $45.85 Million | +32.37pp |
| 2016-12-31 | 38.35% | $22.93 Million | $59.79 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $49.27 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $39.67 Million | -- |
About Scynexis Inc
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory inva… Read more